The Age of Phage: Friend or Foe in the New Dawn of Therapeutic and Biocontrol Applications?

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Mar 6

PMID 33670836

Citations 28

Authors

Ahmad Y Hassan

Janet T Lin

Nicole Ricker

Hany Anany

Affiliations

Soon will be listed here.

Abstract

Extended overuse and misuse of antibiotics and other antibacterial agents has resulted in an antimicrobial resistance crisis. Bacteriophages, viruses that infect bacteria, have emerged as a legitimate alternative antibacterial agent with a wide scope of applications which continue to be discovered and refined. However, the potential of some bacteriophages to aid in the acquisition, maintenance, and dissemination of negatively associated bacterial genes, including resistance and virulence genes, through transduction is of concern and requires deeper understanding in order to be properly addressed. In particular, their ability to interact with mobile genetic elements such as plasmids, genomic islands, and integrative conjugative elements (ICEs) enables bacteriophages to contribute greatly to bacterial evolution. Nonetheless, bacteriophages have the potential to be used as therapeutic and biocontrol agents within medical, agricultural, and food processing settings, against bacteria in both planktonic and biofilm environments. Additionally, bacteriophages have been deployed in developing rapid, sensitive, and specific biosensors for various bacterial targets. Intriguingly, their bioengineering capabilities show great promise in improving their adaptability and effectiveness as biocontrol and detection tools. This review aims to provide a balanced perspective on bacteriophages by outlining advantages, challenges, and future steps needed in order to boost their therapeutic and biocontrol potential, while also providing insight on their potential role in contributing to bacterial evolution and survival.

Citing Articles

Enhancing phage therapy by coating single bacteriophage-infected bacteria with polymer to preserve phage vitality.

Lin S, Xie G, He J, Meng L, Pang Y, Liu J Nat Biomed Eng. 2025; .

PMID: 40000896 DOI: 10.1038/s41551-025-01354-3.

Anti-Infective Bacteriophage Immobilized Nitric Oxide-Releasing Surface for Prevention of Thrombosis and Device-Associated Infections.

Gondil V, Ashcraft M, Ghalei S, Kumar A, Wilson S, Devine R ACS Appl Bio Mater. 2025; 8(2):1362-1376.

PMID: 39895136 PMC: 11836933. DOI: 10.1021/acsabm.4c01638.

Characterization of Enterobacter phage vB_EcRAM-01, a new Pseudotevenvirus against Enterobacter cloacae, isolated in an urban river in Panama.

Victoria-Blanco E, Gonzalez-Gomez J, Medina-Sanchez J, Martinez A, Castro Del Campo N, Chaidez-Quiroz C PLoS One. 2024; 19(12):e0310824.

PMID: 39739645 PMC: 11687723. DOI: 10.1371/journal.pone.0310824.

Molecular characterization and safety properties of multi drug-resistant Escherichia coli O157:H7 bacteriophages.

Oluwarinde B, Ajose D, Abolarinwa T, Montso P, Njom H, Ateba C BMC Microbiol. 2024; 24(1):528.

PMID: 39695941 PMC: 11657129. DOI: 10.1186/s12866-024-03691-w.

What, how, and why? - anti-EHEC phages and their application potential in medicine and food industry.

Necel A, Dydecka A, Topka-Bielecka G, Wesolowski W, Lewandowska N, Bloch S J Appl Genet. 2024; 66(1):219-240.

PMID: 39527365 PMC: 11762087. DOI: 10.1007/s13353-024-00918-4.

References

Gyles C . The growing problem of antimicrobial resistance. Can Vet J. 2012; 52(8):817-20. PMC: 3135024. View

Shkoporov A, Ryan F, Draper L, Forde A, Stockdale S, Daly K . Reproducible protocols for metagenomic analysis of human faecal phageomes. Microbiome. 2018; 6(1):68. PMC: 5892011. DOI: 10.1186/s40168-018-0446-z. View

Schmelcher M, Loessner M . Application of bacteriophages for detection of foodborne pathogens. Bacteriophage. 2014; 4(1):e28137. PMC: 3919822. DOI: 10.4161/bact.28137. View

Luepke K, Suda K, Boucher H, Russo R, Bonney M, Hunt T . Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2016; 37(1):71-84. DOI: 10.1002/phar.1868. View

Rahman M, Kim S, Kim S, Seol S, Kim J . Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling. 2011; 27(10):1087-93. DOI: 10.1080/08927014.2011.631169. View

Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A . Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009; 18(6):237-8, 240-3. DOI: 10.12968/jowc.2009.18.6.42801. View

Argudin M, Deplano A, Meghraoui A, Dodemont M, Heinrichs A, Denis O . Bacteria from Animals as a Pool of Antimicrobial Resistance Genes. Antibiotics (Basel). 2017; 6(2). PMC: 5485445. DOI: 10.3390/antibiotics6020012. View

Gerba C . Quaternary ammonium biocides: efficacy in application. Appl Environ Microbiol. 2014; 81(2):464-9. PMC: 4277564. DOI: 10.1128/AEM.02633-14. View

Carlton R, Noordman W, Biswas B, de Meester E, Loessner M . Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol. 2005; 43(3):301-12. DOI: 10.1016/j.yrtph.2005.08.005. View

10.

Ishino Y, Krupovic M, Forterre P . History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. J Bacteriol. 2018; 200(7). PMC: 5847661. DOI: 10.1128/JB.00580-17. View

11.

Shkoporov A, Hill C . Bacteriophages of the Human Gut: The "Known Unknown" of the Microbiome. Cell Host Microbe. 2019; 25(2):195-209. DOI: 10.1016/j.chom.2019.01.017. View

12.

Suzuki S, Yoshikawa M, Imamura D, Abe K, Eichenberger P, Sato T . Compatibility of Site-Specific Recombination Units between Mobile Genetic Elements. iScience. 2020; 23(1):100805. PMC: 6957869. DOI: 10.1016/j.isci.2019.100805. View

13.

Malik D, Sokolov I, Vinner G, Mancuso F, Cinquerrui S, Vladisavljevic G . Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017; 249:100-133. DOI: 10.1016/j.cis.2017.05.014. View

14.

Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R . The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol. 2005; 30(1):23-6. DOI: 10.1111/j.1365-2230.2004.01600.x. View

15.

Vinay M, Franche N, Gregori G, Fantino J, Pouillot F, Ansaldi M . Phage-Based Fluorescent Biosensor Prototypes to Specifically Detect Enteric Bacteria Such as E. coli and Salmonella enterica Typhimurium. PLoS One. 2015; 10(7):e0131466. PMC: 4506075. DOI: 10.1371/journal.pone.0131466. View

16.

Hyman P . Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth. Pharmaceuticals (Basel). 2019; 12(1). PMC: 6469166. DOI: 10.3390/ph12010035. View

17.

Callanan J, Stockdale S, Shkoporov A, Draper L, Ross R, Hill C . RNA Phage Biology in a Metagenomic Era. Viruses. 2018; 10(7). PMC: 6071253. DOI: 10.3390/v10070386. View

18.

Larsson D, Andremont A, Bengtsson-Palme J, Brandt K, de Roda Husman A, Fagerstedt P . Critical knowledge gaps and research needs related to the environmental dimensions of antibiotic resistance. Environ Int. 2018; 117:132-138. DOI: 10.1016/j.envint.2018.04.041. View

19.

Kretzer J, Schmelcher M, Loessner M . Ultrasensitive and Fast Diagnostics of Viable Cells by CBD Magnetic Separation Combined with A511:: Detection. Viruses. 2018; 10(11). PMC: 6266503. DOI: 10.3390/v10110626. View

20.

Pedulla M, Ford M, Houtz J, Karthikeyan T, Wadsworth C, Lewis J . Origins of highly mosaic mycobacteriophage genomes. Cell. 2003; 113(2):171-82. DOI: 10.1016/s0092-8674(03)00233-2. View